Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
448 stopped studies mapped to Primary Malignant Liver Neoplasm and descendants · 93% state a reason
Over the 448 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00465842 | Protein Biomarker in Hepatocellular Carcinoma | — | terminated | Apr 25, 2007 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Loss of funding due to difficulty with recruitment and participant retention. | Enrollment / accrual |
| NCT02748304 | Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With… | N/A | terminated | Apr 22, 2016 | Fudan University | The enrollment of this study was slow. With the approval of lenvatinib in HCC,many patients choose… | Enrollment / accrual |
| NCT02828124 | A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer | Phase 1 / Phase 2 | terminated | Jul 11, 2016 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT03779100 | Lenvatinib Plus PD-1 Antibody for Unresectable ICC | Phase 2 | suspended | Dec 19, 2018 | Shi Ming | Protocol modification | Other (stated, no rule matched) |
| NCT01600196 | Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous… | Phase 4 | terminated | May 16, 2012 | Sun Yat-sen University | not stated | Not stated |
| NCT02220088 | The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a… | Phase 2 / Phase 3 | terminated | Aug 19, 2014 | Sun Yat-sen University | protocol violation | Other (stated, no rule matched) |
| NCT03035006 | Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein… | Phase 1 / Phase 2 | terminated | Jan 27, 2017 | Taiwan Liposome Company | Current study design couldn't support futher development on this indication. | Other (stated, no rule matched) |
| NCT02787954 | Prospective Tumor Response Evaluation(Liver) | — | terminated | Jun 1, 2016 | The University of Texas Health Science Center, Houston | PI transferred to another institution and did not take this study with him. | Other (stated, no rule matched) |
| NCT02254681 | Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC | Phase 2 | terminated | Oct 2, 2014 | Allina Health System | lack of funding | Funding |
| NCT02599909 | Gut Microbiota in People With Hepatocellular Carcinoma (HCC) | — | withdrawn | Nov 9, 2015 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02967523 | Surefire Precision Infusion System Registry | — | terminated | Nov 18, 2016 | Surefire Medical, Inc. | not stated | Not stated |
| NCT03345225 | A Clinical Study of Precision TACE (P-TACE) With Surefire | N/A | withdrawn | Nov 17, 2017 | University of Miami | Funding | Funding |
| NCT01425996 | A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced… | Phase 1 / Phase 2 | terminated | Aug 30, 2011 | Taiwan Liposome Company | not stated | Not stated |
| NCT02011126 | Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors | Phase 2 | withdrawn | Dec 13, 2013 | Children's Oncology Group | IND no longer available. | Other (stated, no rule matched) |
| NCT02057874 | 3-Tesla MRI Response to TACE in HCC (Liver Cancer) | N/A | terminated | Feb 7, 2014 | Vanderbilt-Ingram Cancer Center | Funding unavailable | Funding |
| NCT00832637 | Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers(Gem-ox) | Phase 2 | terminated | Jan 30, 2009 | New Mexico Cancer Research Alliance | Low accrual | Enrollment / accrual |
| NCT03168152 | Randomized Trial Comparing Stereotactic Body Radiation Therapy to Microwave Ablation for… | N/A | withdrawn | May 30, 2017 | University of Michigan Rogel Cancer Center | No patients were accrued to the trial | Enrollment / accrual |
| NCT02748161 | DEB-TACE for Hepatocellular Carcinoma(QED) | N/A | terminated | Apr 22, 2016 | Surefire Medical, Inc. | Low enrollment | Enrollment / accrual |
| NCT02702960 | Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow… | Phase 2 | withdrawn | Mar 9, 2016 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | This study was withdrawn due to lack of necessary resources from the liver transplant surgical… | Other (stated, no rule matched) |
| NCT02690350 | An Open Study Assessing the Safety and Tolerability of U3-1784 | Phase 1 | terminated | Feb 24, 2016 | Daiichi Sankyo | Program discontinued for business reasons (not safety). | Safety / toxicity |
| NCT01259024 | The LC Bead Trial; Transarterial Chemoembolization of Hepatocellular Carcinoma (HCC)With… | N/A | terminated | Dec 13, 2010 | Washington University School of Medicine | inability to obtain CMS approval | Other (stated, no rule matched) |
| NCT00459108 | Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by… | Phase 2 | terminated | Apr 11, 2007 | National Cancer Institute (NCI) | Halted early for futility. | Efficacy / futility |
| NCT02149771 | Combination Treatment for Advanced Liver Cancer | Phase 3 | withdrawn | May 29, 2014 | Shanghai Zhongshan Hospital | Insufficient funding | Funding |
| NCT01710293 | Intervention Protocol for Automated Point-of-Care Surveillance of Outpatient Delays in…(PACT CREATE 3) | N/A | withdrawn | Oct 19, 2012 | VA Office of Research and Development | Unable to obtain data needed to run the RCT; project never began recruitment | Enrollment / accrual |
| NCT03081039 | A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant… | Phase 3 | withdrawn | Mar 15, 2017 | University of Louisville | Competing study | Other (stated, no rule matched) |
| NCT00878215 | Clinical Application of Image-Guided Liver Surgery | Phase 2 | terminated | Apr 8, 2009 | Washington University School of Medicine | The image-guidance system became commercially available | Other (stated, no rule matched) |
| NCT01956864 | Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer | Phase 1 | withdrawn | Oct 8, 2013 | Johns Hopkins University | PI transferred from Georgetown to Johns Hopkins University. No participants enrolled at either… | Enrollment / accrual |
| NCT02908165 | Randomized Phase II Trial of Chemoembolization and Sorafenib | Phase 2 | withdrawn | Sep 20, 2016 | Yale University | A future study will be taking place using the same patient population. | Other (stated, no rule matched) |
| NCT01012362 | Study of Pazopanib and Ixabepilone in Patients With Solid Tumors | Phase 1 | terminated | Nov 13, 2009 | Masonic Cancer Center, University of Minnesota | PI left institution. | Investigator |
| NCT02406508 | Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib… | Phase 2 | withdrawn | Apr 2, 2015 | Delcath Systems Inc. | No enrollment in the study | Enrollment / accrual |
| NCT02549755 | 11C-acetate for Treatment Response After Radiotherapy for HCC | Phase 2 | terminated | Sep 15, 2015 | Justin Sims | Poor enrollment | Enrollment / accrual |
| NCT00003530 | Antineoplaston Therapy in Treating Patients With Primary Liver Cancer | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | Slow accrual | Enrollment / accrual |
| NCT02958163 | Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)(HepSTAR) | Phase 2 | terminated | Nov 8, 2016 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | lack of recruitment | Enrollment / accrual |
| NCT02026362 | Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients…(HCC DC CTL) | Phase 1 / Phase 2 | suspended | Jan 3, 2014 | HRYZ Biotech Co. | Interim analysis | Efficacy / futility |
| NCT02585687 | Liver Perfusion MRI With Quantification of Tumoral Perfusion for Early Assessment of the…(ETAFIRM) | N/A | terminated | Oct 23, 2015 | Hospices Civils de Lyon | problems with enrollment | Enrollment / accrual |
| NCT01489410 | Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma | N/A | withdrawn | Dec 9, 2011 | University of Minnesota | Insufficient staff | Other (stated, no rule matched) |
| NCT01668017 | A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein… | Phase 1 | terminated | Aug 17, 2012 | Merck KGaA, Darmstadt, Germany | The sponsor decided not to conduct the expansion part of trial (part 2) | Sponsor / business decision |
| NCT02821533 | Chemoembolization for Hepatocellular Carcinoma | Phase 2 | terminated | Jul 1, 2016 | Chinese University of Hong Kong | Poor case accrual | Enrollment / accrual |
| NCT01191385 | GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar… | — | withdrawn | Aug 30, 2010 | Bayer | Study is officially cancelled bevore FPFV. | Other (stated, no rule matched) |
| NCT02959359 | DAA in the Risk of Recurrence After Curative Treatment of HCC | Phase 4 | withdrawn | Nov 9, 2016 | Taipei Veterans General Hospital, Taiwan | The supplies of study drug were halted by Gilead Sciences Ltd. | Other (stated, no rule matched) |
| NCT01419795 | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed… | Phase 2 | terminated | Aug 18, 2011 | Fred Hutchinson Cancer Center | Low accrual | Enrollment / accrual |
| NCT00787787 | Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic… | Phase 2 | terminated | Nov 10, 2008 | University of Washington | not stated | Not stated |
| NCT02856568 | Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With… | Phase 1 | withdrawn | Aug 5, 2016 | Mayo Clinic | Site dropped study | Other (stated, no rule matched) |
| NCT01005875 | Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma(RAD 0901) | N/A | terminated | Nov 2, 2009 | University of Alabama at Birmingham | Sponsor(Bayer)did not wish to continue with study due to slow accrual. Therefore, there is… | Enrollment / accrual |
| NCT01942083 | A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to… | Phase 1 | terminated | Sep 13, 2013 | Korea Otsuka Pharmaceutical Co., Ltd. | Company decision | Sponsor / business decision |
| NCT01379521 | Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC(TRACER) | Phase 2 | terminated | Jun 23, 2011 | Novartis Pharmaceuticals | The study was terminated due to low enrollment. This resulted in the study being underpowered and… | Enrollment / accrual |
| NCT02227914 | Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced… | Phase 1 / Phase 2 | withdrawn | Aug 28, 2014 | Amgen | Study stopped due to administrative reasons | Other (stated, no rule matched) |
| NCT00455091 | A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma | — | terminated | Apr 3, 2007 | National Health Research Institutes, Taiwan | No cases enrollment | Enrollment / accrual |
| NCT01171482 | Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular… | Phase 2 | terminated | Jul 28, 2010 | Seoul National University Hospital | There were problems with national reimbursement policies. | Other (stated, no rule matched) |
| NCT02997956 | Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing… | Phase 1 / Phase 2 | withdrawn | Dec 20, 2016 | University of Michigan Rogel Cancer Center | funding issues | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 15, 2019source: clinicaltrials